Corbus Pharmaceuticals Holdings, Inc.

Equities

CRBP

US21833P3010

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:45:48 27/06/2024 am IST			5-day change	1st Jan Change
44.12 ^USD	-0.51%		+3.42%	+630.63%

02:01pm	B. Riley Initiates Coverage on Corbus Pharmaceuticals With Buy Rating, $85 Price Target	MT
24/06	Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to S&P Biotechnology Select Industry Index	CI

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Barbara White as Chief Medical Officer and Head of Research

August 18, 2021 at 05:36 pm IST

On August 16, 2021, Barbara White, M.D., Chief Medical Officer and Head of Research of Corbus Pharmaceuticals Holdings, Inc. submitted a notice of resignation to the Company to accept a position with another company.

Latest news about Corbus Pharmaceuticals Holdings, Inc.

B. Riley Initiates Coverage on Corbus Pharmaceuticals With Buy Rating, $85 Price Target	05:31pm	MT
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to S&P Biotechnology Select Industry Index	24/06	CI
Transcript : Corbus Pharmaceuticals Holdings, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 02:40 PM	13/06
RBC Raises Price Target on Corbus Pharmaceuticals Holdings to $82 From $77, Maintains Outperform, Speculative Risk	11/06	MT
Corbus Pharmaceuticals Reaches 2-Year High After Drug Results	03/06	DJ
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $80 From $60, Maintains Outperform Rating	03/06	MT
Corbus Pharmaceuticals Presents Positive Clinical Update on SYS6002 (CRB-701) at ASCO Conference	01/06	CI
RBC Initiates Corbus Pharmaceuticals Holdings at Outperform With Speculative Risk Qualifier, $77 Price Target	13/05	MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $60 From $58, Maintains Outperform Rating	08/05	MT
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Certain Restricted Stock Units of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01/05	CI
Certain Warrants of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01/05	CI
Certain Options of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01/05	CI
Certain Common Stock of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01/05	CI
Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC	02/04	CI
Corbus Pharmaceuticals Files Mixed Shelf	14/03	MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $58 From $51, Maintains Outperform Rating	13/03	MT
Health Care Climbs on Risk Appetite -- Health Care Roundup	13/03	DJ
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03	CI
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03	CI
North American Morning Briefing : Inflation Data -2-	12/03	DJ
North American Morning Briefing : Powell Still in -2-	07/03	DJ
Jefferies Upgrades Corbus Pharmaceuticals Holdings to Buy From Hold	06/03	MT
Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer	29/02	CI
Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024	07/02	CI

Chart Corbus Pharmaceuticals Holdings, Inc.

Duration

Period

Chart Corbus Pharmaceuticals Holdings, Inc.

More charts

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFÎ² expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.35 USD

Average target price

80.75 USD

Spread / Average Target

+82.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CORBUS PHARMACEUTICALS HOLDINGS, INC.	+630.63%	47Cr
VERTEX PHARMACEUTICALS INCORPORATED	+16.55%	12TCr
REGENERON PHARMACEUTICALS, INC.	+21.60%	12TCr
ARGENX SE	+22.18%	2.7TCr
BIONTECH SE	-21.50%	2.04TCr
GENMAB A/S	-16.89%	1.64TCr
BEIGENE, LTD.	-18.17%	1.59TCr
WUXI APPTEC CO., LTD.	-44.74%	1.56TCr
SAREPTA THERAPEUTICS, INC.	+62.33%	1.49TCr
NEUROCRINE BIOSCIENCES, INC.	+3.43%	1.36TCr

Bio Therapeutic Drugs